Arcadia Biosciences, Inc. · NASDAQ:RKDA
Arcadia Biosciences — Q3 2017 Earnings Presentation
11 slides from Arcadia Biosciences's earnings presentation, Nov 9, 2017
Slide 1: Third Quarter 2017 Financial Results and Business Highlights
Third Quarter 2017 Financial Results and Business Highlights November 9, 2017
Slide 2: Forward-looking statements
Forward-looking statements “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This presentation c ontains forward-looking statements about the company and its products, including statements relating to components of the company’s long-term financial success;; the
Slide 3: Positive momentum continues in Q3
Positive momentum continues in Q3 Licensed CRISPR-Cas9 gene editing technology Advanced commercialization of non-GM wheat health and nutrition traits Arcadia - Dow AgroSciences (DAS) wheat quality trait collaboration Field trials for abiotic stress traits approved and planted in India Regulatory
Slide 4: Increased focus on Health & Nutrition traits with near term revenue potential
Increased focus on Health & Nutrition traits with near term revenue potential CRISPR Edit Commercial Product Germplasm Launch 3-5 y ears Expected Non-GM, non-regulated products majority of forward Fastest to market investment TILLING Allele Line Breeding & Product Discovery Selection Introgressio
Slide 5: Accelerating product development with TILLING and CRISPR-Cas9
Accelerating product development with TILLING and CRISPR-Cas9 TILLING Allele Line Breeding & Product 5-7 y ears Discovery Selection Introgression Launch High Fiber Wheat (Feed) High Fiber Wheat (Bread) Extended Shelf Life Wheat Reduced G luten Wheat (Feed) Reduced Gluten Wheat (Bread) CRISPR Edit
Slide 6: Health & Nutrition: High fiber wheat
Health & Nutrition: High fiber wheat High Fiber Allele Line Breeding & Product Wheat (Bread) Discovery Selection Introgression Launch High fiber white wheat • Low glycemic index Products are in advanced pre-commercial phase • Introgressing into commercial germplasm • Large-scale trials to demonstr
Slide 7: Ag productivity traits advancing with field trials approved and planted in India and Argentina
Ag productivity traits advancing with field trials approved and planted in India and Argentina Regulatory Transgenic Trait Concept Trait Transformation Event Selection Regulatory & Breeding Submissions Product Launch 9-12 y ears (Pre-commercial HB4 Drought Tolerant Soybeans Nitrogen Use Efficiency
Slide 8: Revenue
Revenue Third Quarter First nine m onths Favorable/ (Unfavorable) Favorable/ (Unfavorable) 2017 2016 $ % 2017 2016 $ % Product revenue 82 102 (20) (20%) 482 422 60 14% License revenue 144 218 (74) (34%) 353 510 (157) (31%) Contract research and 363 755 (392) (52%) 1,763 1,716 47 3% government grants
Slide 9: Operating expenses
Operating expenses Third Quarter First Nine Months Favorable/ (Unfavorable) Favorable/ (Unfavorable) 2017 2016 $ % 2017 2016 $ % Cost of product 40 60 20 33% 262 242 (20) (8%) revenues R&D expense 1,749 2,255 506 22% 5,241 6,673 1,432 21% SG&A expense 2,415 2,687 272 10% 8,410 8,882 472 5% Total ope
Slide 10: Key financial results
Key financial results Third Quarter First Nine Months Favorable/(Unfavorable) Favorable/(Unfavorable) 2017 2016 $ % 2017 2016 $ % Total revenues 589 1,075 (486) (45%) 2,598 2,648 (50) (2%) Cost of product revenues 40 60 20 33% 262 242 (20) (8%) R&D expense 1,749 2,255 506 22% 5,241 6,673 1,432 21% S
Slide 11: Thank you!
®D Arcadia BIOS CIEN CE S&S Thank you!